Linperlisib for acquired pure red cell aplasia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new drug, linperlisib, for patients with acquired pure red cell aplasia (PRCA), a condition where the bone marrow stops making red blood cells. It is for patients who have not improved after other treatments. The drug may help the body make red blood cells again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with acquired pure red cell aplasia (PRCA).
- You have tried at least two prior treatments and they did not work or the condition came back.
- Your hemoglobin level is 100 g/L or lower.
- You are not taking certain immunosuppressive drugs (like cyclosporine or sirolimus) at the time of starting, or you can stop them when you enroll.
- If you take steroids (like prednisone), you are on a stable low dose (15 mg/day or less) or have stopped them for at least 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
This trial tests a new drug, linperlisib, combined with standard chemotherapy (CHOP) for people newly diagnosed with a rare type of T-cell lymphoma (nTFHL) who plan to have a stem cell transplant. It aims to see if this combination is safe and effective.
This trial tests a drug called linperlisib combined with standard chemotherapy and immunotherapy for people with large B-cell lymphoma that has come back or not responded to one prior treatment.
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
Hear when a new Acquired Pure Red Cell Aplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.